Objective: We evaluated the ability of minimally invasive, image-guided vacuum-assisted
biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B) …

Background About 40% of women with breast cancer achieve a pathologic complete
response in the breast after neoadjuvant systemic treatment (NST). To identify these women …

Background and objectives: Pathological complete response after neoadjuvant
chemotherapy for women with primary breast cancer is achieved in up to 60%. Identification …

Purpose Improvements in neoadjuvant systemic therapy (NST) for breast cancer patients
have led to increasing rates of pathologic complete response (pCR). The MICRA trial …

Background Neoadjuvant systemic treatment elicits a pathologic complete response (pCR)
in about 35% of women with breast cancer. In such cases, breast surgery may be …

Background This study aimed to explore the ability of a minimal invasive biopsy to diagnose
a pathological complete response (pCR= ypT0) in the breast. Methods Ultrasound-guided …

Background The added value of surgery in breast cancer patients with pathological
complete response (pCR) after neoadjuvant systemic therapy (NST) is uncertain. The …

Importance Image-guided breast biopsy of a residual imaging abnormality or tumor bed after
neoadjuvant chemotherapy (NACT) is increasingly used to assess residual cancer, facilitate …

PURPOSE Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in
40%-70% of women with breast cancer. These patients may not need surgery as all local …

Background Neoadjuvant chemotherapy (NACT) is a standard approach of the
multidisciplinary treatment of breast cancer. Depending on the biological subtype a …